Skip to main content

Table 1 Patient characteristics

From: Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

 

Total

(n = 97)

High TDI

(n = 53)

Low TDI

(n = 16)

AC(-)

(n = 28)

P value

P value

(high vs. low)

Sex (male/female)

62/35

32/21

8/8

22/6

0.122

0.468

Age, years

71 (50–92)

70 (50–85)

68.5 (54–79)

77.5 (59–92)

 < 0.001

0.863

Preoperative CEA

2.6 (0.6–45.2)

2.4 (0.6–45.2)

4.0 (1.5–24.6)

2.7 (1–30.6)

0.507

0.344

Preoperative CA19-9

135 (0.4–4510)

108.4 (0.7–4510)

85.0 (0.4–1511)

198 (20–2650)

0.955

0.891

Operative method

    

0.133a

0.044a

 -PD

64

32

14

18

  

 -DP

28

19

1

8

  

 -TP

5

2

1

2

  

Pathological diagnosis (IDC/inv. IPMC)

68/29

38/15

13/3

17/11

0.179

0.163

Pathological T factor (1/2/3/4)

12/67/12/6

7/35/8/3

1/12/1/2

4/20/3/1

0.324

0.586

ly (0/1/2/3)

12/64/12/9

7/39/5/2

0/9/3/4

5/16/4/3

0.204

0.164

v (0/1/2/3)

9/31/43/14

1/14/28/10

0/2/10/4

8/15/5/0

0.665

0.586

UICC stage

    

0.102b

0.586b

 -IA, IB

2

1

0

1

  

 -IIA

14

6

1

7

  

 -IIB

41

25

5

11

  

 -III

37

19

10

8

  

 -IV

3

2

0

1

  

Pathological lymph node metastasis (positive/negative)

80/17

45/8

15/1

20/8

0.139

0.365

Residual tumor (R0/R1)

86/11

48/5

13/3

25/3

0.592

0.315

Time to start AC after surgery, days

53 (24–399)

48 (27–399)

78.5 (24–110)

none

0.436

0.436

  1. TDI Total dose intensity, PD Pancreatoduodenectomy, DP Distal pancreatectomy, TP Total pancreatectomy, ly Lymphatic permeation, v Blood vessel invasion, AC Adjuvant chemotherapy, IDC Invasive ductal carcinoma, inv. IPMC Invasive intraductal papillary mucinous carcinoma
  2. aPD vs. DP and TP, bStage ≥ IIB vs. < IIB